Wisniewski, David J.
Voeller, Donna
Addissie, Yonit A.
Deshmukh, Sachin Kumar
Wu, Sharon
Lustberg, Maryam B.
Wangsa, Darawalee
Wangsa, Danny
Heselmeyer-Haddad, Kerstin
Greer, Yoshimi Endo https://orcid.org/0000-0002-9822-7240
Sledge, George W.
Lipkowitz, Stanley https://orcid.org/0000-0002-6103-2255
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (ZIA BC 010977)
U.S. Department of Health & Human Services | National Institutes of Health (ZIA BC 010977)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC 010977)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC 010977)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC 010977)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC 010977)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC 010977)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ZIA BC 010977)
Article History
Received: 24 June 2025
Revised: 31 October 2025
Accepted: 12 November 2025
First Online: 25 November 2025
Competing interests
: The authors declare no competing interests.
: All animal aspects of this study were approved by the NCI Animal Care and Use Committee (IACUC number WMB-004). All studies in the Caris dataset were conducted in accordance with guidelines of the Declaration of Helsinki, Belmont report, and U.S. Common rule, and in keeping with 45 CFR 46.101(b)(4), was performed utilizing retrospective, deidentified clinical data. Per WCG IRB, it was considered institutional review board (IRB) exempt with waiver of patient consent. 15,247 breast cancer samples underwent molecular testing at Caris Life Sciences (Phoenix, AZ, USA), a CLIA/CAP-certified laboratory. No specific inclusion criteria or exclusion criteria were applied aside from the requirement for successful sequencing results.